Palto Therapeutics develops SmartCoat, a nanostructured delivery technology designed to protect, traffic, and target siRNAs and other large genetic cargos while reducing toxicity and cost. The company is validating its technology with drug candidates in oncology and rare-disease indications and aims to expand beyond mRNA vaccination uses. Over the next two years Palto plans to advance a SmartCoat-based drug candidate toward Phase 1 clinical trials, with a specific focus on pancreatic cancer. The startup won CHF 150,000 from Venture Kick to develop the latest generation of SmartCoat and to advance collaborations with industrial and academic partners. Palto intends to raise a seed round in 2024 to complete all nonclinical work required to initiate the clinical study. The team includes founders William Wishart, Marcel Blommers, and Helmut Sparrer and collaborates with academic partners and advisors across FHNW, PSI, FMI and others.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2023